Today: 13 May 2026
Browse Category

Pharmaceuticals 24 February 2026 - 25 March 2026

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck will acquire Terns Pharmaceuticals for $53 per share in cash, valuing the company at about $6.7 billion. The deal gives Merck rights to TERN-701, an experimental leukemia drug, as it prepares for Keytruda’s patent expirations in 2028. The offer represents a 6% premium to Terns’ last close and is subject to antitrust review and shareholder approval. Merck expects to close the transaction in the second quarter.
25 March 2026
··
Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk shares fell 1.5% in Copenhagen Thursday despite FDA approval of a higher-dose Wegovy shot. Shares stayed down as Eli Lilly released new obesity drug data and Reuters reported India’s semaglutide patent expiry will allow cheaper generics. Novo expects to launch the 7.2-mg Wegovy in the U.S. in April. Over 40 Indian drugmakers are preparing generic versions as prices are set to drop.
20 March 2026
··
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson shares fell 0.7% to $245.07 Wednesday after its lupus drug nipocalimab received FDA Fast Track status. The stock lagged a broader market rally, with the S&P 500 ETF up nearly 1%. Investors weighed pipeline progress against ongoing legal risks and recent defensive trading. Johnson & Johnson will present at the Barclays Global Healthcare Conference on March 10.
4 March 2026
··
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly shares fell 1% Tuesday to $1,007.73, extending losses ahead of an FDA decision on its oral obesity pill expected in April. Ventyx Biosciences shareholders approved a merger with Lilly, with Nasdaq set to halt Ventyx stock after hours Tuesday and the deal expected to close before Wednesday’s open. The FDA issued warning letters to 30 telehealth firms over ads for compounded weight-loss drugs.
4 March 2026
···
Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.
2 March 2026
····
Merck stock: weekend Keytruda-Welireg data and Gardasil cuts set up Monday trade

Merck stock: weekend Keytruda-Welireg data and Gardasil cuts set up Monday trade

Merck shares closed up 3.8% at $123.82 Friday after reporting new cancer trial results for Keytruda and Welireg, with an FDA decision on the combination set for June 19, 2026. The company also announced about 150 job cuts at a North Carolina Gardasil vaccine plant amid weaker demand. Merck highlighted positive data in kidney, bladder, and ovarian cancer studies. Shares were little changed after hours.
28 February 2026
··
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK shares rose 0.74% to 2,183 pence by 0855 GMT after Japan and China accepted regulatory filings for two experimental liver-disease drugs. The company also agreed to buy Canada’s 35Pharma for $950 million, adding a pulmonary hypertension asset. GSK closed down 2.12% the previous session. Investors await first-quarter results on April 29.
27 February 2026
··
Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.
26 February 2026
··
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK agreed to buy Canada’s 35Pharma for $950 million in cash, adding experimental pulmonary hypertension drug HS235 to its pipeline. GSK shares rose 0.1% to 2,204 pence in early London trading. The deal is subject to regulatory approval in the U.S. and Canada. GSK also reported buying back 462,000 shares as part of its ongoing share repurchase program.
25 February 2026
·
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics shares rose 6.3% to $52.68 Monday ahead of CEO Marino Garcia’s scheduled fireside chat at TD Cowen’s health care conference on March 3. Volume reached about 944,000 shares. Investors are watching for updates on the company’s autoimmune pipeline and trial timelines. The event will be webcast and include one-on-one investor meetings.
24 February 2026
··
1 2 3 4 5 … 40

Stock Market Today

  • Analog Devices (ADI) Stock Valuation Assessment Amid Strong Price Gains
    May 13, 2026, 2:53 PM EDT. Analog Devices (ADI) stock has surged nearly 20% in the past 30 days and delivered an 87.95% total shareholder return over one year, drawing investor attention. The stock trades at $419.65, about 6.8% above its modeled fair value of $392.94, indicating potential overvaluation. Drivers include growth from robotics and automation expanding ADI's addressable market and boosting revenue. However, risks remain from increased competition in China and rising manufacturing and R&D costs that could pressure margins. Investors should weigh ADI's growth potential against these challenges when considering inclusion in portfolios.

Latest articles

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

13 May 2026
Palantir shares fell 4.4% to $129.97 Wednesday as CEO Alex Karp met President Volodymyr Zelenskiy in Kyiv to discuss expanding AI use in Ukraine’s war effort. Kyiv’s Brave1 Dataroom project, launched with Palantir, is training AI models to intercept Russian drones. Russia fired at least 800 drones at Ukraine on Wednesday, killing six. Palantir’s U.S. government and commercial revenue surged in the first quarter.
Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

13 May 2026
Grab shares fell 1.1% to $3.60 in New York after first-quarter revenue beat estimates, rising 24% to $955 million. Profit jumped to $120 million from $10 million a year earlier. Investors weighed strong results against Indonesia’s new 8% ride-hailing commission cap. Grab kept its 2026 revenue and adjusted EBITDA outlook unchanged.
SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

13 May 2026
SoFi acquired PrimaryBid’s technology to expand IPO access for retail investors, confirmed by both companies. SoFi shares fell 2.9% to $15.44 after Truist cut its price target, citing concerns over loan and technology platforms. The acquisition follows a drop in technology-platform accounts and comes as SoFi reported strong first-quarter revenue and member growth. Terms of the deal were not disclosed.

Popular

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

12 May 2026
British American Tobacco shares jumped 5.82% in London to £46.34 after the FDA signaled a softer enforcement stance on some e-cigarette and nicotine pouch products. A U.S. judge also dismissed BAT’s North Korea sanctions case following a $630 million settlement. The FTSE 100 slipped 0.04%. BAT’s U.S.-listed ADR closed up 5.3% at $63.64.
Go toTop